LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Kezdőlap・Részvénylista・Certara Inc

Certara Inc

Lezárt

SzektorEgészségügy

5.18

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

5.01

Maximum

5.29

Fő mutatók
By Trading Economics
Bevétel	-2.9M -8.8M
Értékesítés	3.3M 107M
P/E Szektor átlag	100.714 49.052
Egy részvényre jutó nyereség	-0.06
Profit margin	-8.196
Munkavállalók	1,515
EBITDA	-8.9M 23M

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+50.77% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	37M 835M
Előző nyitás	5.18
Előző zárás	5.18

Hangulat hírek alapján

By Acuity

88%

12%

317 / 344 Rangsor szerint Healthcare

Certara Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. jún. 10. 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

2026. jún. 10. 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026. jún. 10. 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026. jún. 10. 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026. jún. 10. 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

2026. jún. 10. 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

2026. jún. 10. 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026. jún. 10. 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026. jún. 10. 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026. jún. 10. 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026. jún. 10. 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026. jún. 10. 23:38 UTC

Global Equities Roundup: Market Talk

2026. jún. 10. 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

2026. jún. 10. 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026. jún. 10. 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026. jún. 10. 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026. jún. 10. 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

2026. jún. 10. 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. jún. 10. 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. jún. 10. 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. jún. 10. 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026. jún. 10. 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

2026. jún. 10. 20:50 UTC

Financial Services Roundup: Market Talk

2026. jún. 10. 20:50 UTC

Basic Materials Roundup: Market Talk

2026. jún. 10. 20:50 UTC

Health Care Roundup: Market Talk

2026. jún. 10. 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026. jún. 10. 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. jún. 10. 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026. jún. 10. 20:33 UTC

Global Equities Roundup: Market Talk

2026. jún. 10. 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Társak összehasonlítása

Árváltozás

Certara Inc Előrejelzés

Célár

By TipRanks

50.77% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 7.81 USD 50.77%

Magas 10 USD

Alacsony 6 USD

9 Wall Street elemző 12 hónapos célárain alapulva a(z)Certara Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

9 ratings

Vétel

Tartás

Eladás

9 Wall Street elemző célárain alapulva a(z)Certara Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

317 / 344 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.